| [Fire Fighting] Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire. | |
| [Ingestion] Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended. | |
| [Inhalation] If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention. | |
| [Skin] Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes. | |
| [Eyes] If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention. | |
| [Storage] Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage. | |
| [Handling] All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood. | |
| [Inhalation] Pulmonary edema has been reported following buflomedil overdoses. Respiratory depression may occur with buflomedil intoxication. | |
| [Ingestion] Nausea and vomiting are common following therapeutic administration of fenoldopam. | |
| [Personal Protection] Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots. | |
| [Respirators] Use NIOSH/MSHA approved respirator appropriate for exposure of concern. | |
| [Exposure Effects] headache, dizziness and sweating may occur with any of the vasodilators. Peripheral neuropathy has been reported following long term hydralazine therapy. Hyperglycemic, non-ketotic coma may occur with diazoxide. Seizures and coma may occur with buflomedil toxicity. | |
| [Appearance] Yellow needles from methanol. | |
| [Solubility in water] Slightly soluble | |
| [Melting Point] 272 - 275 | |
| [pKa/pKb] 7.83 (pKb) | |
| [Partition Coefficient] 1 | |
| [Usage] Medication. | |
| [Product Name] Hydralazine | |
| [Synonyms] 1(2H)-Phthalazinone, hydrazone 1-Hydrazinophthalazine 1-Phthalazinylhydrazine Apressin Hypophthalin Phthalazin-1-ylhydrazine | |
| [CAS] 86-54-4 | |
| [Formula] C8H8N4 | |
| [Molecular Weight] 160.18 | |
| [EINECS] 201-680-3 | |
| [RTECS] TH8925000 | |
| [RTECS Class] Tumorigen; Drug; Mutagen; Reproductive Effector; Human Data | |
| [Merck] 12,4800 | |
| [Beilstein/Gmelin] 132615 | |
| [Beilstein Reference] 5-25-17-00412 | |
| [Small spills/leaks] Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces. | |
| [Stability] No data. | |
| [Incompatibilities] Strong oxidizing agents. |
Print